Ritonavir News and Research

RSS

Ritonavir, also known as Norvir, is a type of medicine called a protease inhibitor (PI). PIs act by blocking protease, a protein that HIV needs to make more copies of itself. Ritonavir was approved by the FDA on March 1, 1996, for use with other antiretroviral agents in the treatment of HIV infection in adults and children 2 years of age or older. Ritonavir is now approved with other anti-HIV drugs in the treatment of HIV-1 infection in children in individuals over 1 month in age. Studies have shown that ritonavir works as a booster for some other PIs. Taking ritonavir makes it possible to take a lower dose of the other PIs. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.

Oral antivirals Molnupiravir and Nirmatrelvir-Ritonavir lower COVID-19 risks in type 2 diabetes patients

Research investigates the effectiveness of oral antiviral medications, Molnupiravir and Nirmatrelvir-Ritonavir, in treating patients with type 2 diabetes and mild to moderate COVID-19. The study aims to determine the efficacy of these medications in reducing adverse outcomes in this specific population.

24 May 2023

Nanoparticles take aim at COVID-19 with lysosome-targeted delivery

Researchers discuss the use of endo-lysosome-targeted nanoparticles for delivering antiviral therapy to treat coronavirus infections.

15 May 2023

Nirmatrelvir/ritonavir reduces the risk of COVID-19-associated hospitalization

Researchers assess whether nirmatrelvir/ritonavir treatment reduced the risk of COVID-19-related hospitalization.

10 May 2023

Molnupiravir treatment reduces risk of long COVID in high risk patients

Among high-risk individuals, molnupiravir treatment in the acute phase of infection could prevent long COVID.

27 Apr 2023

Nirmatrelvir-ritonavir reduces risk of post-COVID syndrome in non-hospitalized vaccinated patients

Researchers assess the effect of nirmatrelvir plus ritonavir on the occurrence of long COVID.

12 Apr 2023

Is nirmatrelvir treatment of SARS-CoV-2 associated with a lower risk of post–COVID-19 condition?

Researchers performed an observational cohort study using the US Department of Veterans Affairs healthcare databases.

27 Mar 2023

Higher Paxlovid uptake in winter 2022 could have prevented nearly 5,000 deaths

In a recent study published in the JAMA Health Forum, researchers in the United States estimated the reduction in coronavirus disease 2019 (COVID-19) mortality rates after the Paxlovid rollout.

22 Mar 2023

Study reveals why COVID-19 subvariants spread rapidly among previously infected people

The COVID-19 pandemic has killed nearly 7 million people worldwide (1.1 million in the United States) and severely harmed many millions more, though vaccines and antiviral treatments measurably reduced the potential loss of life and health.

22 Mar 2023

Paxlovid is 80% effective when taken within 5 days of severe COVID

In a recent study published in The Lancet’s Infectious Diseases, researchers in the United States evaluated nirmatrelvir–ritonavir treatment effectiveness against hospitalizations and deaths among coronavirus disease 2019 (COVID-19) outpatients in the United States of America (USA).

21 Mar 2023

Study confirms the benefit of Paxlovid as an early-stage treatment to prevent COVID-19 hospitalization

A Kaiser Permanente study confirms the benefit of nirmatrelvir-ritonavir, also known as Paxlovid, as an early-stage treatment to prevent hospitalization for people with mild to moderate COVID-19, regardless of prior immunity or age.

17 Mar 2023

AI-based drug interaction prediction technology analyzes the interaction between Paxlovid ingredients

KAIST (President Kwang Hyung Lee) announced on the 16th that an advanced AI-based drug interaction prediction technology developed by the Distinguished Professor Sang Yup Lee's research team in the Department of Biochemical Engineering that analyzed the interaction between the PaxlovidTM ingredients that are used as COVID-19 treatment and other prescription drugs was published as a thesis.

16 Mar 2023

Rebounding of COVID-19 symptoms and viral load are common among untreated COVID-19 patients

Researchers characterize COVID-19 symptom and viral load rebounds among untreated individuals with mild-to-moderate SARS-CoV-2 infection.

27 Feb 2023

Two newer simplified HIV treatment options found to be at least as effective as the standard of care

Two newer simplified treatment options are at least as effective as current approaches, according to the results of a world-first international clinical trial into second-line HIV therapy led by the Kirby Institute at UNSW Sydney and presented today at the Conference on Retroviruses and Opportunistic Infections in Seattle.

23 Feb 2023

Research reports full efficacy of Sotrovimab against BQ.1.1 viral replication in a non-human primate challenge model

Researchers used a non-human primate model to show that Sotrovimab, a commercial mAb also known as Xevudy, was fully effective against SARS-CoV-2 Omicron BA.5 sub-lineage and its derivatives, such as BQ.1.1.

17 Feb 2023

Nirmatrelvir–ritonavir found to lower COVID-19 severity outcomes

Researchers evaluated the effectiveness of nirmatrelvir–ritonavir in preventing coronavirus disease 2019 (COVID-19) severity outcomes during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant predominance.

16 Feb 2023

Cohort study examines the incidence of SARS-CoV-2 rebound in patients on oral antivirals

Researchers performed a retrospective population-wide cohort study using anonymized data in Hong Kong, China, between February 26 and July 3, 2022.

16 Feb 2023

Nirmatrelvir-ritonavir therapy effective against Omicron BA.4/BA.5

Researchers examine non-hospitalized adult patients with COVID-19 treated with nirmatrelvir-ritonavir.

15 Feb 2023

New insights into the role of T-cells during long COVID

Researchers characterize the trajectory of long COVID in patients eight months after recovering from infection.

14 Feb 2023

Paxlovid can prevent hospitalization and death for patients infected with Omicron variants, study shows

Though many Coloradans are proceeding as though the COVID-19 pandemic is over, the virus continues to circulate, evolve and have an impact-;especially for older adults and those with underlying medical conditions.

13 Feb 2023

What older Americans need to know about taking Paxlovid

A new coronavirus variant is circulating, the most transmissible one yet. Hospitalizations of infected patients are rising. And older adults represent nearly 90% of U.S. deaths from covid-19 in recent months, the largest portion since the start of the pandemic.

18 Jan 2023